Literature DB >> 16466996

Past, present, and future strategies in the treatment of high-grade glioma in children.

Alberto Broniscer1.   

Abstract

Unlike high-grade glioma in adults, these tumors represent a minority of all primary central nervous system neoplasms in the pediatric age group (< 22 years). Treatment is quite challenging because of the resistance of high-grade glioma in children to radiotherapy and chemotherapy. Whereas maximum resection and radiotherapy are the mainstay of treatment for this type of tumor in children > 3 years, the role of chemotherapy is less clear. Despite the use of multimodality therapy, less than 20 percent of these children are long-term survivors. This review provides an overview of relevant past, current and future treatment strategies for high-grade glioma in children.

Entities:  

Mesh:

Year:  2006        PMID: 16466996     DOI: 10.1080/07357900500449702

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  17 in total

1.  Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.

Authors:  Chintan Parekh; Rima Jubran; Anat Erdreich-Epstein; Ashok Panigrahy; Stefan Bluml; Jonathan Finlay; Girish Dhall
Journal:  J Neurooncol       Date:  2010-11-01       Impact factor: 4.130

2.  Impact of vision loss among survivors of childhood central nervous system astroglial tumors.

Authors:  Peter M K de Blank; Michael J Fisher; Lu Lu; Wendy M Leisenring; Kirsten K Ness; Charles A Sklar; Marilyn Stovall; Chris Vukadinovich; Leslie L Robison; Gregory T Armstrong; Kevin R Krull
Journal:  Cancer       Date:  2016-01-11       Impact factor: 6.860

Review 3.  Paediatric gliomas: diagnosis, molecular biology and management.

Authors:  Alexandros Blionas; Dimitrios Giakoumettis; Alexia Klonou; Eleftherios Neromyliotis; Ploutarchos Karydakis; Marios S Themistocleous
Journal:  Ann Transl Med       Date:  2018-06

Review 4.  Challenging issues in pediatric oncology.

Authors:  Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo
Journal:  Nat Rev Clin Oncol       Date:  2011-06-28       Impact factor: 66.675

Review 5.  Molecular characteristics of pediatric high-grade gliomas.

Authors:  Omar Chamdine; Amar Gajjar
Journal:  CNS Oncol       Date:  2014-11

Review 6.  Actionable molecular biomarkers in primary brain tumors.

Authors:  Verena Staedtke; Omar Dildar a Dzaye; Matthias Holdhoff
Journal:  Trends Cancer       Date:  2016-07

7.  Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas.

Authors:  Hui-Qi Qu; Karine Jacob; Sarah Fatet; Bing Ge; David Barnett; Olivier Delattre; Damien Faury; Alexandre Montpetit; Lauren Solomon; Peter Hauser; Miklos Garami; Laszlo Bognar; Zoltan Hansely; Robert Mio; Jean-Pierre Farmer; Steffen Albrecht; Constantin Polychronakos; Cynthia Hawkins; Nada Jabado
Journal:  Neuro Oncol       Date:  2009-10-15       Impact factor: 12.300

8.  Gliomas in children.

Authors:  Jane E Minturn; Michael J Fisher
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

9.  Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.

Authors:  Ronald J Bernardi; Amanda R Lowery; Patrick A Thompson; Susan M Blaney; Jennifer L West
Journal:  J Neurooncol       Date:  2007-09-06       Impact factor: 4.130

10.  Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.

Authors:  Tae-Young Jung; Chae-Yong Kim; Dong-Seok Kim; Young-Shin Ra; Seong-Ho Kim; Hee-Jo Baek; Hyoung-Soo Choi; In-Ah Kim
Journal:  Childs Nerv Syst       Date:  2012-05-11       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.